Main > > >HYPERCHOLESTEROLEMIA *

Cardio.>HeFH (HEterozygous Familial Hyp- ercholesterolemia). Treat.: AlirocuMAb Inj.
Heart Attack Risk Reduction in Cardiac
Disease Patients.
Mechanism: PCSK9 Inhibition.
EU Approval Date : 2015. 09.28.
JP Approval Date : ?
USA Approval Date: 2015. 07.24.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04,22.




Cardio.>HeFH (HEterozygous Familial Hypercholesterolemia). Treat.: Bempe- doic Acid Tab.
Adenosine triphosphate-Citrate Lyase
(ACL) Inhibitor. (Non-Statin)
USA Approval Date: 2020. 02.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.29.




Cardio.>HeFH (HEterozygous Familial Hypercholesterolemia). Treat.: Bempedoic Acid+Ezetimibe Tab.
USA Approval Date: 2020. 02.26.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2020. 02.29.




Cardio.>HeFH/HoFH (HEterozygous Familial Hypercholesterolemia/HOmozygous Familial Hypercholesterolemia). Treat.: Evolocu MAb Inj.
Heart Attack Risk Reduction in Cardiac
Disease Patients.
Mechanism: PCSK9 Inhibition.
AU Approval Date : ?
CA Approval Date : ?
EU Approval Date : 2018. 05.16.
JP Approval Date : ?
USA Approval Date: 2017. 12.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.22.




HoFH (HOmozygous Familial Hypercholes-
terolemia. Treat.: EvinacuMAb-dgnb.
USA Approval Date: 2021. 02.11.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2021. 02.12.




HoFH (HOmozygous Familial Hypercholes- terolemia. Treat.: Lomitapide Capsules.
Heart Attack Risk Reduction in Cardiac
Disease Patents.
AT Launch Date: 2015. 04.30.
EU Approval Date: 2013. 07.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.03.




Cardio.>HoFH (HOmozygous Familial Hyper-cholesterolemia. Treat.: Lomitapide Capsules.
Heart Attack Risk Reduction in Cardiac
Disease Patents.
CA Approval Date: ?
MX Approval Date: ?
USA Approval Date: 2012. 12.
USA Launch Date: 2014. 02.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.03.




Cardio.>Mixed Dyslipidemia & Primary Hyperlipidemia.
is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients.
HyperCholesterolemia.
HyperTriglyceridemia.
Generic Name: PitavaStatin Tablets.
USA Approval Year: 2017.
USA Launch Date: 2nd Quarter 2018.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.27.




Cardio.>Treat.: FenoFibrate Tablets. Brand. (CA)
>to reduce elevated LDL-C Total-C, TG,
and Apo B, and to increase HDL-C in
adult patients
USA Approval Date: 2007. 08.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.01.




Cardio.>Treat.: FenoFibrate Tablets. Brand.
>to reduce elevated LDL-C Total-C, TG,
and Apo B, and to increase HDL-C in
adult patients
(*) Company : AbbVie.
Patent : Expired.
TradeMark: TriCor
Web-Site : www.tricortablets.com/
UpDate: 2019. 04.01.




Cardio.>Treat.: FenoFibrate Tablets.
Generic.
USA Launch Date: 2016. 07.06.
(*) Company: Mylan.
UpDate: 2019. 04.01.




Cardio.>Treat.: FenoFibric Acid DR Cap-
sules.
>to reduce elevated LDL-C Total-C, TG,
and Apo B, and to increase HDL-C in
adult patients.
(*) Company : AbbVie.
Patent : Expired.
TradeMark: Trilipix
Web-Site : www.trilipix.com
UpDate: 2019. 04.01.




Cardio.>Treat.: FluvaStatin.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.22.




Cardio.>Treat.: Omega-3 Phospholipid.
Status: Phase III.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.21.




Cardio.>Treat.: PitavaStatin Tablets.
USA Approval Date: 2009. 08.03.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.22.




Treat.: Cholestyramine for Oral
Suspension USP.
USA Launch Date: 2018. 06.27.
(*) Company : Ani Pharmaceuticals.
UpDate: 2018. 06.28.




Treat.: Colesevelam.HCl Tablets.
Brand. (EU)
EU Approval Date: 2004. 03.10.
EU Launch Date: 2007. 10.23.
Company : Sanofi.
Patent : Expired.
TradeMark: Cholestagel
UpDate: 2019. 04.21.




Treat.: Colesevelam.HCl Tablets.
Brand. (USA)
USA Approval Date: 2000. 05.26.
Company : Daiichi Sankyo.
Patent : Expired.
TradeMark: Welchol.
Web-Site : welchol.com
UpDate: 2019. 04.21.




Treat.: Colesevelam.HCI Tablets.
Generic. (USA)
USA Approval & Launch: 2018. 05.17.
(*) Company : Amneal Pharma.
www.amneal.com
UpDate: 2018. 05.18.




Treat.: Colesevelam.HCI Tablets.
Generic.
USA Launch Date: 2018. 10.09.
(*) Company: Dr. Reddy s Laboratories
UpDate: 2018. 10.10.




Treat.: Statin. AtorvaStatin.
Company : Dexcel Pharma.
TradeMark: Litorva.
UpDate: 2019. 04.21.




Treat.: Statin. AtorvaStatin.
Company : Dr. Reddy Labs.
TradeMark: Atocor
UpDate: 2019. 04.21.




Treat.: Statin. AtorvaStatin.
Company : Pfizer.
Patent : Expired.
TradeMark: Lipitor.
Web-Site : www.lipitor.com
UpDate: 2019. 04.21.




Treat.>Statin>FluvaStatin. Authorized
Generic.
USA>Launch Date: 2015. 10.16.
(*) Company: Sandoz
UpDate: 2019. 04.22.




Treat.: Statin>LovaStatin.
Company : Merck.
Patent : Expired.
TradeMark: Mevacor
UpDate: 2019. 04.22.




Treat.>Statin>PravaStatin
Company : Bristol Myers Squibb.
Patent : Expired
TradeMark: Pravachol
UpDate: 2019. 04.22.




Treat.: Statin>RosuvaStatin.
Company : AstraZeneca.
Patent : Expired.
TradeMark: Crestor.
UpDate: 2019. 04.22.




Treat.: Statin>SimvaStatin.
Company : Merck
Patent : Expired
TradeMark: Zocor.
UpDate: 2019. 04.22.




Treat.: Statin>SimvaStatin+Ezetimibe
Company : Merck
Patent : Expired
TradeMark: Vytorin
UpDate: 2019. 04.22.


>HYPERCHOLESTEROLEMIA *'s products
This section has no products